SARS-CoV-2 Spike (996-1004) - Antimicrobial Peptides - AMP
The SARS-CoV-2 spike protein is present on the outside of the virus particles and can bind to angiotensin-converting enzyme II (ACE2) present on the host cells. The C-terminal receptor binding domain (RBD) of the spike protein binds to the N-terminal peptidase M2 domain of ACE2. This receptor binding results in the internalisation of the virus-receptor complex and is, therefore the mechanism of entry of SARS-CoV-2 into host cells. The spike protein residues LITGRLQSL (996-1004) from C have been identified as a T-cell epitope with a predicted HLA restriction. Immune targeting of confirmed epitopes may potentially offer protection against SARS-CoV-2 and help the development of vaccines for long-lasting immunity.
Technical specification
![]() |
Sequence : | H-LITGRLQSL-OH |
![]() |
MW : | |
![]() |
Purity : | > 95% |
![]() |
Counter-Ion : | TFA Salts |
![]() |
Delivery format : | Lyophilized |
Price
| Product | Size | Price € | Price $ |
| CRB1001819-0.5 mg | 0.5 mg | 141€ | 170$ |
| CRB1001819-1 mg | 1 mg | 193€ | 232$ |




